Cochlear Limited (ASX:COH): Implant Demand, FY26 Earnings and Product Developments

Aditi Sarkar

20 October 2026 04:53 PM AEDT

Cochlear Limited (ASX:COH): Implant Demand, FY26 Earnings and Product Developments

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Cochlear Limited (ASX:COH) reported FY26 sales revenue of AUD 2,343.4 million.
Underlying net profit was AUD 322.4 million; statutory net profit was AUD 147.3 million.
Cochlear implant volumes rose 5% to 56,692 units as product mix affected revenue.
FY27 guidance envisages underlying net profit of AUD 330–350 million.

Cochlear Limited designs and supplies implantable hearing technologies, sound processors and related services for people with hearing loss. The company’s FY26 results reflect a year of new implant technology launches, mixed surgical demand and increased research spending. On 20 October 2026, Cochlear Limited (ASX:COH) was trading at AUD 139.47, up 5.22% for the session according to the stated market quotation. Its August full-year release reported reduced earnings despite growth in implant units, while management outlined cost measures and an FY27 operating outlook.

Company Business

Cochlear operates across cochlear implants, services and acoustics. The implant business supplies surgically implanted hearing systems, while services includes replacement sound processors and accessories for existing recipients. Acoustics incorporates bone-conduction solutions such as the Osia platform. Cochlear Limited (ASX:COH) serves developed healthcare markets and emerging markets, where reimbursement policies, surgical capacity and product mix differ. The geographic profile means exchange rates and healthcare access can affect reported results. In FY26, implants contributed 61% of sales revenue, services 27% and acoustics 12%.

Recent Development

The Nucleus Nexa System was a central FY26 commercial development. Cochlear reported that the system accounted for more than 95% of implant sales in developed markets by June 2026, following its market rollout. The company also continued work on clinical programs involving a drug-eluting electrode and a totally implantable cochlear implant. In September 2026, the company announced a research milestone of more than one million hours of patient experience across its fully implantable hearing technology programme. For Cochlear Limited (ASX:COH), these activities form part of product development rather than a guarantee of regulatory approval or commercial sales.

Financial Performance and Sector Context

FY26 sales revenue was AUD 2,343.4 million, down 1% on a reported basis but up 2% in constant currency. Cochlear implant units increased 5% to 56,692, although implant revenue fell 2% as reported and was flat in constant currency. Services revenue reached AUD 634.9 million, up 6% in constant currency. Acoustics revenue was AUD 273.3 million, up 1% in constant currency. The difference between volumes and revenue partly reflected a higher proportion of lower-priced emerging-market implants.

Gross margin declined to 71% from 74%, reflecting sales mix, manufacturing overhead recovery and currency effects. Underlying net profit decreased 22% to AUD 322.4 million; statutory net profit declined to AUD 147.3 million. Reported operating expenses increased 5% to AUD 1,251.4 million, including transitional costs. Research and development expenditure rose 15% to AUD 323.2 million. Cochlear Limited (ASX:COH) reported operating cash flow of AUD 368.0 million and free cash flow of AUD 263.5 million. Net cash at June 2026 was AUD 187.7 million.

Healthcare industry conditions were uneven. The company identified surgical backlogs in parts of Western Europe, insurance approval delays and changes in referral activity as influences on developed-market procedures. China’s volume-based procurement arrangements affected average selling prices, while conflict disrupted some Middle East activity. These issues create different demand and pricing conditions across regions; they do not establish a cause for the 20 October share price change.

Risks to Consider

Cochlear Limited (ASX:COH) faces risks from variations in clinical referrals, delays in surgery, hospital capacity and changes to healthcare reimbursement. Lower selling prices or an increased mix of lower-tier systems can pressure margins. Manufacturing utilisation, product rollout costs, currency fluctuations and execution of restructuring measures can also affect earnings. Development-stage technologies require clinical testing and regulatory assessment. The FY26 investment revaluation and cloud program costs illustrate how non-operating or significant items may influence statutory profit.

What to Watch Next

For FY27, management forecast low single-digit constant-currency sales revenue growth and underlying net profit of AUD 330–350 million. The company indicated a gross margin range of approximately 70–71% and capital expenditure of AUD 100–110 million. Cochlear Limited (ASX:COH) also expects further cloud-system spending and continued R&D investment. Its annual general meeting is scheduled for 26 October 2026. Subsequent disclosures can clarify implant demand, referral initiatives, acoustics product launches, cost reductions and the progression of clinical development programs.

Key Insights

FY26 combined higher implant shipments and improved free cash flow with lower margins and earnings. Cochlear Limited (ASX:COH) is addressing varied market conditions through its Nexa rollout, healthcare referral initiatives and operating cost changes. The next reporting periods will show how those actions appear in volumes, geographic sales mix and profitability. The published FY27 range represents company guidance rather than an assured outcome.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.